# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a missi...
Piper Sandler analyst Christopher Raymond maintains Ardelyx (NASDAQ:ARDX) with a Neutral and raises the price target from $8...
Wedbush analyst Laura Chico maintains Ardelyx (NASDAQ:ARDX) with a Outperform and raises the price target from $13 to $14.
Raymond James analyst Ryan Deschner maintains Ardelyx (NASDAQ:ARDX) with a Outperform and raises the price target from $11 t...
Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 34...